According to the Market Statsville Group (MSG), the global dexmedetomidine market size is expected to grow from USD 1,178.20 million in 2022 to USD 5,076.29 million by 2033, at a CAGR of 14.20% from 2023 to 2033. Dexmedetomidine is a useful sedative agent with analgesic properties, hemodynamic stability, and ability to recover respiratory function in mechanically ventilated patients facilitating early weaning. Increasing number, the old age population all over the world and increasing hypertension, depression, and other hectic disease in early stage or in childhood or in adulthood has also boosted the market growth over the forecasting period. In addition, the use of dexmedetomidine in an aesthetic in the healthcare industry. Dexmedetomidine allows for a smooth emergence from anesthesia by attenuating agitation, cough, and hemodynamic changes in children and adults, this has also booted the market growth over the forecasting period all over the world. Moreover, higher doses of dexmedetomidine may result in a higher incidence of hypotension or bradycardia. Due to these reasons the market has shown a negative growth impact in this market for the upcoming years.
Dexmedetomidine is a new generation highly selective 2-adrenergic receptor (AR) agonist linked with sedative and analgesic sparing effects, decreased delirium and agitation, perioperative sympatholytic, cardiovascular stabilizing effects, and respiratory function preservation.
Dexmedetomidine is a sedative medication that is offered under the brand names Precede and others. Dexmedetomidine is used in the treatment of cats, dogs, and horses by veterinarians for similar reasons. In humans, it is also used to treat acute agitation caused by schizophrenia or bipolar I or II condition. It is a sympatholytic medication that, like clonidine, operates as an agonist of 2-adrenergic receptors in some areas of the brain. It was created by the company Orion Pharma.
The COVID-19 pandemic has had a profound impact on the healthcare industry and has created new challenges for healthcare organizations. The dexmedetomidine market has also been affected by the pandemic, and the market is expected to grow at a slower rate as a result of the economic impact of the pandemic. The economic consequences of the lockdown measures have had a significant influence on the Dexmedetomidine market. Supply chain problems have been common, limiting the Dexmedetomidine industry's growth possibilities. One of the key challenges facing the dexmedetomidine market is the decreased demand for healthcare services as a result of the pandemic. The decreased demand for healthcare services has led to a decrease in the demand for dexmedetomidine.
Due to its sedative, anxiolytic, analgesic, sympatholytic, and stable hemodynamic profile, dexmedetomidine is used as an adjuvant for premedication, especially in patients who are susceptible to preoperative and perioperative stress. Dexmedetomidine (DEX) is a highly selective 2-adrenergic agonist with sedative and analgesic characteristics and few respiratory side effects. In the critical care unit and operation room, it is used as a sedative. Dexmedetomidine is an appealing adjuvant medication for anaesthesia in obese patients who are at higher risk of postoperative respiratory difficulties due to its opioid-sparing impact and lack of respiratory effects. Dexmedetomidine reduces oxygen demand during surgery (up to 8%) and after surgery (up to 17%). In additional, Intraarticular dexmedetomidine enhances the quality and duration of postoperative analgesia in patients having arthroscopic knee surgery. Due to these reasons this market has seen a upsurge over the period of time.
Dexmedetomidine's side effects are mostly limited to hemodynamic changes. Hypertension, bradycardia, and hypotension are caused by pre- and postsynaptic 2-receptor activation, which results in vasoconstriction, vasodilation, and reflex bradycardia (Ebert et al., 2000). Long-term dexmedetomidine usage causes receptor hypersensitivity and upregulation. A withdrawal syndrome of anxiousness, agitation, headaches, and hypertensive crisis can develop with sudden cessation. In individuals with extensive cardiac block and ventricular failure, dexmedetomidine is not advised. The FDA has classed it as a category C pregnancy risk; therefore, it should be taken with great caution in pregnant women. A major limitation of the use of dexmedetomidine is its long-lasting effects and its hemodynamic effects. These highly adverse effects has hindered the market growth over the forecast period all over the world.
Diverse effects of DEX include sedation, analgesia, anxiolysis, sympatholytic, cardiovascular stabilization and reduction of aesthetic requirements with preservation of respiratory function. These features have given DEX an advantage over other sedatives, such as opioids and benzodiazepines. Its clinical use has been focused on two major scenarios: periprocedural sedation in anaesthesia and “light to mild” sedation in the ICU. The unique properties of DEX make it suitable for sedation and analgesia during the entire perioperative state in a wide range of procedures. DEX can be used as premedication, as an aesthetic adjunct for anaesthesia or as a postoperative sedative process. In addition, dexmedetomidine can be used in many types such as in ICU, Invasive Mechanical Ventilation, Non-Invasive Ventilation, Delirium, and many others. Due to these many uses this has played an important role in medical industry and has created a lot of opportunity for the market player in the upcoming year.
The study categorizes the dexmedetomidine market based on type and application area at the regional and global levels.
Based on the product type, the market is bifurcated into intensive care unit sedation, procedural sedation, and others. The intensive care unit sedation segment is expected to dominate the market share in 2022 in the global dexmedetomidine market. Dexmedetomidine induces sedation while maintaining reusability in ICU patients, and its use has resulted in a shorter time to extubating, a lower incidence of agitated delirium, delirium prevention, and lower mortality than other agents administered in certain populations. DEX is considered as a promising agent optimized for sedation in ICU. Due to these reasons this segment has register the largest market share over the forecasting period.
Based on the regions, the global dexmedetomidine market has been segmented across North America, Europe, Asia-Pacific, Middle East & Africa, and South America. North America is projected to account for the highest market share in 2022. In North America, the demand for dexmedetomidine is growing as the government implements healthcare reform initiatives that aimes to improve the efficiency and quality of healthcare services. The North American healthcare sector is also growing rapidly, driven by increasing healthcare spending and a growing population.
The dexmedetomidine market is extremely cutthroat, and significant competitors in the sector are using strategies including product launches, partnerships, acquisitions, agreements, and growth to enhance their market positions. Most sector businesses focus on increasing their operations worldwide and cultivating long-lasting partnerships.
Frequently Asked Questions
Want to Review Complete Market Research Report
Budget constraints? Get in touch with us for special pricing
Request for Special PricingCustomize this Report
Related Reports
Metagenomics Sequencing Market 2021: Industry Size, Regions, Emerging Trends, Growth Insights, Opportunities, and Forecast By 2027
Mar 2024Medical Cannabis Oil Market 2021: Industry Size, Regions, Emerging Trends, Growth Insights, Development Scenario, Opportunities, and Forecast By 2027
Mar 2024Novel Vaccine Delivery System Market 2021: Industry Size, Regions, Emerging Trends, Growth Insights, Opportunities, and Forecast By 2027
Mar 2024Lysosomal Storage Disease Treatment Market 2021: Industry Size, Regions, Emerging Trends, Growth Insights, Development Scenario, Opportunities, and Forecast By 2027
Mar 2024Single-Use Bioprocessing Market 2022: Industry Size, Emerging Trends, Regions, Growth Insights, Opportunities, and Forecast By 2033
Mar 2024